Elucida Oncology, Inc. Elucida Oncology, Inc.

Shining a Light on Cancer

Elucida Oncology™ is focused on transforming outcomes for patients with primary solid tumor and metastatic cancer. We are leveraging the novel Target or Clear™ capabilities of our ultra-small C-Dot cancer-targeting particle platform across diagnostic imaging, surgical and a wide range of therapeutic applications.

Learn More
scroll

Key Numbers

1,688,780

Projected new cancer
cases in 2017 1

600,920

Projected lives
lost in 2017 1

39.6%

Approximate number who will be diagnosed with cancer at some point in their lifetime2

Source

  1. In the U.S. American Cancer Society, Cancer Facts and Figures, 2017. United States data only. Excludes basal cell and squamous cell skin cancers and in situ carcinomas except urinary bladder.
  2. NIH, NCI: About Cancer > Understanding Cancer > Statistics. United States data only.

From the October 29, 2014 cover of Science Translational Medicine. Illustration: V. Altounian, C. Bickel/ Science Translational Medicine. Reprinted with permission from AAAS.

A Novel Platform

An entirely new class of cancer-targeted, ultra-small, precision-engineered particles.

Learn More

Synergistic Leadership

Scientific, clinical and business strength combined to provide outstanding leadership.

Learn More

In Clinical Use

Early human clinical data has been published and clinical trials are currently enrolling.

Learn More

Pipeline

The adaptability of our platform and our globally-recognized scientific team has led to advanced preclinical programs across diagnostic imaging, surgical and therapeutic applications.

Learn More